151 related articles for article (PubMed ID: 17324336)
21. Low-binding alleles of Fcgamma receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients.
Zuñiga R; Ng S; Peterson MG; Reveille JD; Baethge BA; Alarcón GS; Salmon JE
Arthritis Rheum; 2001 Feb; 44(2):361-7. PubMed ID: 11229467
[TBL] [Abstract][Full Text] [Related]
22. Fc gamma RIIa, IIIa and IIIb polymorphisms in Turkish children susceptible to recurrent infectious diseases.
Ozturk C; Aksu G; Berdeli A; Kutukculer N
Clin Exp Med; 2006 Mar; 6(1):27-32. PubMed ID: 16550341
[TBL] [Abstract][Full Text] [Related]
23. Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy.
Stork AC; Notermans NC; van den Berg LH; Schellevis RD; Niermeijer JM; Nederend M; Leusen JH; van der Pol WL
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):918-20. PubMed ID: 24487381
[TBL] [Abstract][Full Text] [Related]
24. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
25. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
26. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Weng WK; Levy R
J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
[TBL] [Abstract][Full Text] [Related]
27. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus.
Edberg JC; Langefeld CD; Wu J; Moser KL; Kaufman KM; Kelly J; Bansal V; Brown WM; Salmon JE; Rich SS; Harley JB; Kimberly RP
Arthritis Rheum; 2002 Aug; 46(8):2132-40. PubMed ID: 12209518
[TBL] [Abstract][Full Text] [Related]
28. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
29. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
Anolik JH; Campbell D; Felgar RE; Young F; Sanz I; Rosenblatt J; Looney RJ
Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
[TBL] [Abstract][Full Text] [Related]
30. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.
Zhang W; Wang X; Li J; Duan MH; Zhou DB
Chin Med J (Engl); 2010 Jan; 123(2):198-202. PubMed ID: 20137370
[TBL] [Abstract][Full Text] [Related]
31. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
32. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
33. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.
Cooper N; Stasi R; Cunningham-Rundles S; Cesarman E; McFarland JG; Bussel JB
Br J Haematol; 2012 Aug; 158(4):539-47. PubMed ID: 22775462
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.
Weng WK; Levy R
Leuk Lymphoma; 2009 May; 50(5):723-7. PubMed ID: 19452316
[TBL] [Abstract][Full Text] [Related]
35. No association of Fc gamma RIIa, Fc gamma RIIIa and Fc gamma RIIIb polymorphisms with MS.
Breij EC; van der Pol WL; van Winsen L; Jansen MD; Dijkstra CD; van de Winkel JG; Uitdehaag BM
J Neuroimmunol; 2003 Jul; 140(1-2):210-5. PubMed ID: 12864991
[TBL] [Abstract][Full Text] [Related]
36. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].
Zhang W; Wang X; Duan MH; Li J; Zhou DB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):400-2. PubMed ID: 19567119
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin G fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis.
Brun JG; Madland TM; Vedeler CA
J Rheumatol; 2002 Jun; 29(6):1135-40. PubMed ID: 12064825
[TBL] [Abstract][Full Text] [Related]
39. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
[TBL] [Abstract][Full Text] [Related]
40. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
Park SJ; Hong YS; Lee JL; Ryu MH; Chang HM; Kim KP; Ahn YC; Na YS; Jin DH; Yu CS; Kim JC; Kang YK; Kim TW
Oncology; 2012; 82(2):83-9. PubMed ID: 22327884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
